SSY GROUP (02005) has announced that its Vitamin B12 injection has received approval from China's National Medical Products Administration to add a 1ml:1mg specification. The product also passed the evaluation for consistency in quality and efficacy of generic drugs, making SSY GROUP the second domestic company to achieve this approval. Vitamin B12 injection is primarily used to treat megaloblastic anemia caused by a lack of intrinsic factor, and it can also serve as an auxiliary treatment for nervous system disorders such as subacute combined degeneration and neuritis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments